L & L Bio Co., Ltd., Ningbo, China
Clinical trials sponsored by L & L Bio Co., Ltd., Ningbo, China, explained in plain language.
-
New Dual-Action antibody enters early human trials for tough cancers
Disease control Recruiting nowThis early-stage study is testing an experimental drug called LB1410 in people with advanced solid tumors or lymphoma that hasn't responded to standard treatments. The drug is a bispecific antibody designed to block two proteins (PD-1 and TIM-3) that can help cancer hide from the…
Phase: PHASE1 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two experimental drugs (LB1410 and LB4330) given together to people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink or control tumors. About 194 adults will take part, and the…
Phase: PHASE1, PHASE2 • Sponsor: L & L Bio Co., Ltd., Ningbo, China • Aim: Disease control
Last updated May 11, 2026 20:41 UTC